UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 21, 2003
Shire Pharmaceuticals Group plc
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
England and Wales
- --------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
0-29630 98-0359573
(Commission File Number) (IRS Employer Identification No.)
Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code 44 1256 894 000
------------------------------
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events
Shire Pharmaceuticals Group plc has issued the press release attached as
Exhibit 99.1 and incorporated by reference herein.
Item 7. Financial Statements and Exhibits
(c) Exhibits. The following exhibit is filed herewith:
99.1 Press Release dated March 21, 2003
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: March 21, 2003 SHIRE PHARMACEUTICALS GROUP PLC
By: /s/ Angus Charles Russell
--------------------------------
Name: Angus Charles Russell
Title: Group Finance Director
EXHIBIT INDEX
Number Description
99.1 Press Release dated March 21, 2003